Bill Anderson becomes CEO of Bayer
Plus: High leaving AskBio, and updates from Verily, PhRMA, MOMA and more
Bill Anderson will succeed Werner Baumann as head of Bayer AG (Xetra:BAYN), joining the German company’s board of management April 1 and becoming CEO June 1. Anderson stepped down as CEO of Roche Pharmaceuticals on Dec. 31, a position he had held since 2019, before which he was CEO of Genentech Inc. Baumann will retire at the end of May after 35 years at the company, seven spent in the top post.
Gene therapy veteran Katherine High departed Bayer’s Asklepios BioPharmaceutical Inc. (“AskBio”) in December after serving nearly two years as the company’s president of therapeutics, potentially adding to the small but in-demand pool of available management talent with cell and gene therapy experience. High continues to serve as a visiting professor at The Rockefeller University. ...